Skip to main content
. 2019 Sep 20;11:8589–8602. doi: 10.2147/CMAR.S186002

Figure 1.

Figure 1

(A) The expression level of KCNK15-AS1 was lower in the tumor tissue (P<0.05). (B) The expression level of KCNK15-AS1 was lower in the stage III and stage IV cases (P<0.05). (C) KCNK15-AS1 overexpression inhibited proliferation in the BGC-823 cells (P<0.05). (D) KCNK15-AS1 overexpression promoted apoptosis in the BGC-823 cells. (E) KCNK15-AS1 overexpression inhibited proliferation in the SCG7901 cells (P<0.05). (F) KCNK15-AS1 overexpression promoted apoptosis in the SCG7901 cells. (G) KCNK15-AS1 overexpression decreased the mRNA and protein levels of MMP-2, MMP-9, and bcl-2 and increased the level of Bax in the BGC-823 cells (P<0.05; P<0.05). (H) KCNK15-AS1 overexpression decreased the mRNA and protein levels of MMP-2, MMP-9, and bcl-2 and increased the level of Bax in the SGC-7901 cells (P<0.05; P<0.05).

Abbreviation: FITC, fluorescein isothiocyanate.